powered by Wowoo

LIFEX

LIFE + PHOENIX

Project name of LIFEX is given from a
hope that everyone’s
lives will revive like a phoenix even in their
later years.

PRESALE CLOSED! Thank you for your participation.

ABSTRACT

LIFEX RESEARCH PTE. LTD. (“The Company”) provides services related to new medical care including personalized/ regenerative medicine to customers as a business operator. He Company seeks to solve various problems such as “the medical expenses increasing issue” surrounding this business environment through utility-typed electronic token from “the combination technology of blockchain and Artificial Intelligence” point of view, and at the same time will raise funds for that.

By introducing this token system, the medical researchers and developers can receive the benefit of medical Big Data, and the token holder who is a participant of this service platform ecosystem can be rewarded the "incentives of new medical care services" in the future.

This utility-typed electronic token used for this service platform will be issued and operated using the Wowoo system which is the crypto currency issuing system.

LIFEX

PROJECT

Service provided by the operator

Business of LIFEX

LIFEX records and stores knowledge such as medical big data,
its analysis results, results obtained from it in block chains, and provides useful information to stakeholders and commercial users.
Medical big data can be used not only for development of specific medicines and preventive medicine by discovering common points such as diseases in the large universe, but also for regenerative medicine and personalized medicine.

Social Issues

As a social problem across the globe, there are:
•Increase in the medical expenses,
•and prolonged lives.

Our lives may be extended but may not be so healthy either.
Needless to say, that everyone would rather live longer being healthy, that is without being conscious of your body of suffering.

Reference: World medical cost estimate

left: Population transition of the world / right: Relationship between GDP and medical expenditure
LIFEX
Source

Reference: Trends in the size of medical products market in major countries

LIFEX
Source

Solution

As a clue to solving these coming issues, Genetic information is becoming an important keyword.

Professor Yamanaka of Japan proposed, by introducing four factors (Oct3/4, Xox2, C-Myc, KIf4) into mouse embryonic fibroblasts, they we able to generate mouse induced pluripotent stem cell (iPS Cell: induced pluripotent stem cell) that had differentiation and pluripotent characteristics like that of ES cells (http://www.cira.kyoto-u.ac.jp/j/research/yamanaka_summary.html), of many possibilities that lie ahead. However, in reality, the technology for returning from human cells to iPS cells has not been firmly established, and we are still searching for the gene codes to be found which would return to each cell.

In order to manage our health in a more appropriate way, we must connect the needed information to establish medical treatments surrounding the gene and those people who are in need of them. Those institutions with this information must connect them to one. However, publishing information held by each research institution will also mean that they must give up their concessions. Then, the years, expenditures and expenses that they spent would not be rewarded. Also, even on the user side, the procedure for receiving new medical treatments properly would be very complicated and still needs to wait for the time to catch up.

Therefore, LIFEX uses blockchain technology to construct LIFEX BC Network that will connect researcher’s results fairly with people who are in need of gene therapy. Then, we would collect information on what kind of research and results has been made across the world in the iPS cell and therapeutic protein based on Vector virus technology, and allowing for hospitals, universities, and medical professionals to access to these information that are stocked within the LIFEX BC Network.

LIFEX Ecosystem Diagram

LIFEX

New medical care

Regenerative medicine is a medical regeneration of organs from iPS cells and is entering the stage of preclinical studies now. As an indispensable peripheral technology, there is a vector technology that transports iPS cells to RNA that proliferates cells outside the cell membrane while preventing the adverse effect of altering DNA of cell nucleus. In personalized medicine, genome analysis and omics analysis allow you to perform optimal medical care in accordance with individual differences in the effectiveness of treatment / medicine and side effects.

Patented technology

World patent for protein gene vector (technology provided by I’ROM Group)

LIFEX

We will be promoting this as a Vector DNA Research project.

Ultimately, general users can connect their health data and data at the hospital to this network, connect to the latest information on gene therapy, and if necessary receive advice from Artificial Intelligence of recommended therapy methods and facilities.

Medical Big data and AI

Medical Big data and AI

Of the medical big data, we can obtain conventional trial results that statistically process large scale population data for the development and preventive medicine of potent medicine effective for a certain disease. Processing with specific disease purpose / multiplayer data will be the center. Meanwhile, in personalized medicine, causal relationships of diseases and the like are determined based on genetic factors, acquired factors such as characteristics and lifestyle habits, various kinds of data such as anamnesis and injuries to individual patients, Discovery of optimal medical care, processing for specific individual purpose and various kinds of data will be the center. Artificial intelligence (AI) and high-speed arithmetic processing are indispensable in processing these medical big data.
In the inference by AI, there is a process of constructing a hypothesis model from less data such as preliminary estimation and a process of posteriori estimation that enhances the accuracy of the hypothesis model based on new data input one after another. Generally, there are algorithms such as a neural network and deep learning which restrict Boltzmann machine with preliminary estimation and back propagation by feedback of error such as back propagation to improve precision. Genetic algorithm etc. are famous for optimal search by AI.
By utilizing these AI techniques, it is possible to estimate the hypothesis model of how individual differences are occurring in personalized medicine, then input a large amount of various data of the individual to increase posterior estimation accuracy , The disease and its factors and the precision with respect to the disease can be improved and it is possible to derive the optimal treatment method and the optimal treatment facility etc. from the choices of various medical means. However, the computational algorithm of AI is progressing rapidly, so we always make use of the latest technology.

LIFEX will not limit on using particular artificial intelligence technology.

LIFEX will not limit on using particular artificial intelligence technology.

We will provide artificial intelligence API and a special format on the blockchain on the AI Chain, which will enable to analyze by connecting LIFEX BC Network to each available and appropriate Artificial intelligence. Using this AI Chain, LIFEX himself analyzes using artificial intelligence technology and requests analytical cooperation from artificial intelligence engineers around the world. For iPS cell research and therapeutic protein research, we are initially working with the research network based on the vector virus technology of I’ROM Group of Japan. I’ROM Group has already distributed their research kit to 100 locations around the world, so we plan to promote cooperation with these organizations.
In cooperation with LEGO (Life Intelligence Escrow Governance Organization) and Personal Data Security Assurance Organization, gene authentication technology is implemented in LIFEX BC Network as BC Biometrics. It is necessary to be based on genetic information in order to provide proper matching of health data and gene therapy data in a safe way.
Personal Attribute information (PAI) is decentralized and care is taken to enable authentication in a form that individuals cannot be identified. The institution connecting to this LIFEX BC Network will only be able to access the necessary information.

LIFEX BC Network
LIFEX BC Network has an API and SDK (development tool) for connecting to that information and exchanging information and providing hospitals, universities, medical staff, and private health service companies allowing access to information while allowing various services to be implemented.

Beneficiaries of this project

Beneficiaries of this project

The following stakeholders are expected to benefit from the deliverables of this project.

• Data provider (Donor):
The desired data provider can register his genetic data, biometric data, medical record data, lifestyle habit data, etc. as a preparation for his future medical care I can do it. It can be an important guideline for receiving optimal medical care for himself as personalized medicine when suffering in the future, and in future iPS cells (artificial pluripotent stem cells) and animals We are aiming to be able to receive regenerative medicine by ES cell (embryonic stem cell) origin. Unlike insurance which is monetary guarantee, this is convenience for self-treatment.

• Medical institutions:
Medical institutions can carry out optimal treatment based on the data provided by donors and stored and their analysis results and referring to the knowledge accumulated by LIFEX. Not only the clinician but also the research doctor can receive data and knowledge on anonymous basis.

• Medicine companies/Medical equipment companies:
The use as big data greatly contributes to the development department of pharmaceutical companies and medical equipment companies. The population at the clinical stage needs a huge number of monitor participants (clinical trial participants) to verify their effects and side effects. Medical big data stored on the block chain is authentic data that cannot be tampered with, and it can improve efficiency of the trial phase before regulatory approval. As a result, the cost reduction effect is reflected in the drug price, which will encourage environments where more patients can use new drugs at an appropriate reasonable price.

• Supplemental Foods Companies:
Plant-derived and animal-derived health components provide a gradual effect, unlike chemicals. Verifying these effects is a difficult task even considering cost effectiveness and time required. Medical Big Data is useful for cohort studies that analyze incidence rates of populations exposed to specific factors and populations not exposed to them in analytical epidemiology and comparing incidence rates. Cohort study area that has long settled and has long settled in the past, such as race which intensively takes salt intake and not so, race which actively ingests specific natural foods, and race which is not so Although it was difficult to find out, it is considered to be of great use to cohort research since it can save a lot of individual lifestyle habit data on the block chain.

FUTURE IMAGE

In the future, we will collect genes from a drop of blood and perform individual authentication with LIFEX BC Network, so that general user and iPS cell information and therapeutic protein information are tightly linked and will be further utilized. Also, through analysis of genes and biological data, if treatment is required, it will be possible to prepare therapeutic proteins in appropriate vectors and deal with them in advance. If advance therapy is not fulfilled, we should be able to recommend the optimal combination by culturing sites, organs, organs from iPS cells or stem cells and transplanting to a medical institution with that technology. Depending on the holding amount of LIFEX, the priority of receiving services may be determined in the future.

At the next stage, we plan to construct a facility to cultivate iPS cells from the blood of the user who wishes to do so and freezing and preserving iPS cells in an appropriate state. In the distant future, it is also possible to collect the blood of the baby child, authenticate it, analyze the gene, calculate the probability of what kind of disease at what time, and treat the gene in advance It will be possible.

However, the environmental factors are also casually related to the expression of genes, and there are still not yet known factors, such as mutations, and most of the categories must be dealt with ethical problems, so we must carefully seek for the positive future model cases that will benefit people’s lives.

Use cases

These are some use cases from the world that LIFEX could bring in the future:

LIFEX Use case

Use case 1

John Smith connected his health device to LIFEX BC Network, automatically uploaded the number of steps, heart rate, blood pressure, sleeping time every day, pictures of what he ate and the calculated calories. One day there was an alert from LIFEX’s AI agent that the risk level of disability of his livers within the year has increased, and a suggestion that it was better to see an appropriate medical institution. When he visited both medical institution, one from a neighbor, and one that were recommended, abnormal values were certainly seen in precision examination from both doctors.
After receiving medical treatment from a specialist, the examination value returned to normal and the future risk were alleviated. John decided with a relief that he will continue to upload his health data to LIFEX BC Network and also allow medical institutions to upload examination data and notified medical institutions.

LIFEX Use case

Use case 2

Adam Smith suffered from diabetes. As the stage advanced, one step before dialysis was needed, he continued diet therapy while communicating with a managed nutritionist introduced from a hospital where he was admitted. After learning about LIFEX, he informed the medical institution to connect to LIFEX BC Network.
Within a few minutes he got information on new medicine to improve his condition. He had learned that this new drug is not yet available for general sale and can be tried for free if it is a clinical trial basis.
He applied for clinical trials if there was a possibility to go without dialysis. Medical institution was recommended by LIFEX 's AI agent, treatment started using this new drug under the support of doctors, pharmaceutical companies and medical institutions. After that, he was confident that he symptoms improved and his decision was correct.
After several years, LIFEX's AI agent notified him that he would be paid of incentives towards the contribution he made via the data he provided, for the new drug was released to the market and made great profit. That amount was to be paid in cryptocurrency. He was surprised that the amount when converted in Fiat currencies were not a small amount.

LIFEX Use case

Use case 3

XX Gene laboratory cultured iPS cells, described genetic code in it, and studied which part, organ, organs it would become. They found a gene code that branches to the surface membrane of the lens of the eyeball, which was newly discovered this time, until the stage where its reproducibility, safety and certainty are verified. Continuing partnership with LIFEX, connecting its research process to LIFEX BC Network, it secured the right of information and made it available to other research institutions. From LIFEX 's AI agent, they were informed of receiving an offer from a medical institution in Europe to corporate in a case to reproduce eyeballs from a patient’s iPS cells using the genetic code they have discovered.
Costs were to be paid from a pharmaceutical company planning to sell the project itself as a package and an appropriate allocation by LIFEX Mining Distribution is paid by the cryptocurrency LIFEX. XX Gene Laboratory accepted participation in this project and released its research results to this node. XX Gene Laboratory incorporates this LIFEX Mining Distribution technology into the laboratory and each will receive the LIFEX appropriately according to the contribution degree of the laboratory and its laboratory staffs.

COUNCIL

LIFEX Council is an organization to review Token Sale issuing companies and projects on the Service Platform and to review the social nature of the project, and the Councilors are block chain engineers, proprietary technologies, founder, initial investment It consists of houses etc.

Fujimaru Nichols

Yoshitake Awa
CEO / Lifex Research Pte. Ltd.

Yoshitake Awa has a vast experience and knowledge in sales and marketing through his 30 years of career and has been based in Japan, US and Singapore. He started his career at Nomura Securities headquarters in Tokyo as a Japanese equity analyst in 1984. Subsequently was stationed at Nomura Securities International in their San Francisco and Los Angeles offices as a Japanese and American equities broker. Besides Nomura, Awa has held various positions in global investment banks, such as Barclays de Zouete Wedd, Credit Lyonnais Securities, BNP Paribas, and engaging in equity sales and securities lending businesses. In 2004, he moved to Singapore to join UOB Asset Management (UOBAM) where he was in charge of marketing UOBAM financial products to Japan. He also worked at Asian Management (Singapore) for their Japanese equity long/short fund as the Stock Loan trader. He currently works at AP Investment Advisory Services Pte. Ltd. Mr. Awa was graduated from Seattle University in the US where he acquired Bachelor of Arts in Business Administration in 1983.

Fujimaru Nichols

Winston Patrick Eric Koike

Winston Patrick Eric Koike is the Director of AP Investment Advisory Services Pte. Ltd. based in Singapore and he is also a director of AP Advisory Services Ltd. (Hong Kong), Kenzo Capital in Japan and Kenzo GmbH in Germany. Winston started his career as an intern to the Parliamentary vice Minister of Finance in Japan. He then proceeded to work in the financial industry. He worked with Morgan Stanley as in various capacities there including sales manager for their Securities Lending Desk in Tokyo. Following this he worked for State Street Bank and Trust in Tokyo involving himself with structuring of both domestic and off-shore financial products and the marketing and sales of these products. In 1995 he was offered the role of starting and managing the Securities Lending Division for the HSBC, in Hong Kong. Whilst at HSBC, he was one of the founding members of the industry association, PASLA (Pan Asia Securities Lending Association) and held various posts including Company Secretary and Chairman of the membership committee. However after spending over ten years in the finance industry, circumstances made him take over his family business involved with Defense. He successfully grew the business and in 2008, transferred the defense businesses to a long time partner company listed on the Tokyo Stock Exchange.
Winston has a BA in Economics from the Keio University in Tokyo.

Fujimaru Nichols

Fujimaru Nichols
CEO / Wowoo Pte. Ltd.

Fujimaru is responsible for running Wowoo Operator. He is very keen in international business as well as cryptocurrency space. “One impression can end a war. One impression can melt ice wall in the mind.“ After the experience of international business fields, he decided to involve in this blockchain world.
And presently, he strongly leads the team with this principle and is spreading use of this new token in the real world.

Yuya Sugiura

Yuya Sugiura
Marketing / Wowoo Pte. Ltd.

Yuya has more than 3 years of experience in the cryptocurrency industry. He leads marketing of this business with broad knowledge and tough spiritual strength, which based on various experiences including a researcher and a medical specialist.
He is also concurrently CEO of Tokennews.

James MacWhyte

James MacWhyte

Mr. James MacWhyte has been Chief Product Officer at breadwallet LLC since September 29, 2017. Mr. MacWhyte is a talented technologist and absorber of information. Previously, he was associated with Coinbase, Kraken, Tokyo Bitcoin Meetup.

Tetsuya Oishi

Tetsuya Oishi

He is the most well-known crypto blogger in Japan. Starting blog from 2013, he focused on crypto currency and blockchain technology. His Twitter's followers more than 30,000. He introduced new technology concepts such as Pow and Blockchain, Ethereum and ICO for the first time to Japan.
As an angel investor, he is investing in several companies, domestic and overseas projects. He majored in computer science at Keio University.

Naohisa Yahagi
Deputy Head of Clinical Research Network Office, National Center for Child Health and Development

Naohisa was born in Palo Alto, USA in 1974. He studied in Belgium as an AFS exchange student in 1991. He earned M.D. from Keio University School of Medicine in 2000 and Ph.D. from Keio University School of Medicine in 2004.
Naohisa finished the medical management program at University of Tokyo in 2004 (first on the list). He was invited as a scholar and finished Harvard Business School MHD in 2011. Then he started to develop medical management system for developing countries such as India, South Africa, UAE, Laos and Mongolia.Now, Naohisa serves as Deputy Head of Clinical Research Network Office, Department of Project Management and Pharmaceutical Development at National Center for Child Health and Development.

Tsugumine Shu
President / ID Pharma Co., Ltd.

Tsugumine Shu is one of one of the inventors of the Sendai virus vector. He led the research team successfuly and developed the vector for gene therapy at DNAVEC Research in 1999. At present, clinical trials are in progress for three type of drug candidates he and his colleagues have developed in collaboration; that is, an AIDS vaccine, a drug for ischemic limbs and a drug for retinitis pigmentosa.
He obtained his doctorate in 1989 from Tokyo University of Agriculture and Technology, and, as a postdoctoral fellow at Plantech Research Institute of Mitsubishi Kasei Corporation, engaged in the development of recombinant plants. Through his achievements a recombinant rice (1991), study of the infection mechanism of rice dwarf virus (1992), he has been engaged in the development of vectors for gene therapy at the ID Pharma since 1996.

Adam Vaziri
Founder and CEO of QRC HK

Adam Vaziri is a blockchain lawyer who was labelled a ‘bitcoin pioneer’ by Bitcoin Magazine, and a blockchain compliance specialist. Adam is engaged in spreading blockchain regulatory environment for cryptocurrency. The bitlegal.io he runs is a global tracker for blockchain law and featured by CNN and Washington Post. In 2013, as the director of UKDCA, he made efforts to spread regulations in the UK.
With experience of many license work, the licenses optimized for blockchains has been issued successfully in Isle of Man. Adam is a tireless blockchain entrepreneur and has set up blockchain lab called ” Chain of Things” which is specialized in IoT, and “Blockpass” which is a block chain passport specialized in KYC.

Toyotaka Mori
CEO / I’ROM Group

Mr. Mori is the founder of I’ROM Group and his company was established in 1997 for the purpose of commissioning and mediating clinical trials of pharmaceuticals and started a clinical facility support project.
In 2003, I’ROM went public in the Jasdaq market and in 2005 the shares were listed on the 1rst section of the Tokyo Stock Exchange.
He worked for Bayer Pharmaceutical after graduated Meiji Pharmaceutical University. After career ups at Gurlan Pharmaceutical, Mr. Mori founded I’ROM Holdings at the age of 38 and became CEO. He is a person of full of vitality and focuses on the development of the company for realizing healthy and affluent lives for people.

Masatsune Okajima
Vice President / MediciNova, Inc

Mr. Okajima joined MediciNova in September 2006. Before joining MediciNova, Mr. Okajima served as Deputy General Manager, Daiwa Securities SMBC Co., Ltd. From 1999 through 2002, Mr. Okajima served as Manager, Daiwa Securities’ SB Capital Markets Co., Ltd. (currently Daiwa Securities SMBC Co., Ltd.). As Deputy General Manager, Mr Okajima was involved in pivotal phases of initial public offerings, subsequent public offerings, corporate bond issuances, and mergers & acquisitions. In addition, he handled Investors Relations and stock trading. From 1996 to 1999, Mr. Okajima served as Manager, Sumitomo Capital Securities Co., Ltd. Mr. Okajima served in various positions at Sumitomo Bank, Ltd. (currently Mitsui Sumitomo Bank) between 1991 and 1996. Mr. Okajima graduated with a B.S. Degree from the Department of Science and Technology, Tokyo Science University.

Takayuki Nakamura

Takayuki Nakamura
CEO / OKEIOS Co., Ltd.

The company mission "provides the medical care that is most suitable for each one of the world".
I apply a block chain technology in the field of health care and provide the organization where an individual manages the health data.
I become value of the digital information mainly on health care data and the life log and develop business model when an individual can receive incentive by performing the agreement formation of the data offer.

Company History
2016 June The OKEIOS Co., Ltd., the representative director assumption of office.
2016 December The patent application about data usage using BCN (block chain network), a system and the program.
2017 March It is adopted by "Microsoft Bizspark Plus" of Microsoft Co., Ltd.
2017 September I announce it at "the 17th Japan diabetes information society annual academic meeting".
2017 July I announce it at "Meeting for the study about the next-generation health care strategy in the Kyushu area". In problem "the local governments research and development about the construction of a health instruction system performing a risk prediction and targeting using AI to a base in insurer receipt data and healthy information" that national university corporation Hiroshima University acts as research and development representative as an allotment researcher participation.
2018 March I announce it at "Kyushu healthcare industry battle front 2018".

ROADMAP

  • Q4 2018

    Vector DNA Research Phase1.0
    LIFEX BC Network Ver1.0
    Ai Chain Ver1.0
    BC Biometrics Ver1.0

  • Q2 2019

    iPS cells Collect research results

  • Q3 2019

    Vector DNA Research Phase2.0
    LIFEX BC Network Ver2.0
    Ai Chain Ver2.0
    BC Biometrics Ver2.0

  • Q1 2020

    Therapeutic protein Collect research results

  • Q2 2020

    iPS cells Collect research results

  • Q3 2020

    Vector DNA Research Phase3.0
    LIFEX BC Network Ver3.0
    Ai Chain Ver3.0
    BC Biometrics Ver3.0

  • Q1 2021

    Therapeutic protein Collect research results

  • Q2 2021

    Vector DNA Research Phase4.0
    LIFEX BC Network Ver4.0
    Ai Chain Ver4.0
    BC Biometrics Ver4.0

WHITEPAPER

CONTACT

LIFEX RESEARCH PTE. LTD.

CEO: Yoshitake Awa

info@lifex.bio